BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 20518608)

  • 1. Use of growth factors for the treatment of Parkinson's disease.
    Yasuda T; Mochizuki H
    Expert Rev Neurother; 2010 Jun; 10(6):915-24. PubMed ID: 20518608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurotrophic factor therapy for Parkinson's disease.
    Rangasamy SB; Soderstrom K; Bakay RA; Kordower JH
    Prog Brain Res; 2010; 184():237-64. PubMed ID: 20887879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease.
    Kordower JH
    Ann Neurol; 2003; 53 Suppl 3():S120-32; discussion S132-4. PubMed ID: 12666104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of gene therapy for Parkinson's disease: neurobiologic issues and new developments in gene transfer methodologies.
    Kang UJ
    Mov Disord; 1998; 13 Suppl 1():59-72. PubMed ID: 9613721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trophic factor gene therapy for Parkinson's disease.
    Kordower JH; Bjorklund A
    Mov Disord; 2013 Jan; 28(1):96-109. PubMed ID: 23390096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy for Parkinson's disease.
    Lawlor PA; During MJ
    Expert Rev Mol Med; 2004 Mar; 6(5):1-18. PubMed ID: 15000692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracerebral transplantation of genetically engineered cells for Parkinson's disease: toward clinical application.
    Yasuhara T; Date I
    Cell Transplant; 2007; 16(2):125-32. PubMed ID: 17474294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cell therapy and other neuroregenerative strategies in Parkinson's disease (II)].
    Mínguez-Castellanos A; Escamilla-Sevilla F
    Rev Neurol; 2005 Dec 1-15; 41(11):684-93. PubMed ID: 16317638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain.
    Kojima H; Abiru Y; Sakajiri K; Watabe K; Ohishi N; Takamori M; Hatanaka H; Yagi K
    Biochem Biophys Res Commun; 1997 Sep; 238(2):569-73. PubMed ID: 9299553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [AAV vector-mediated gene transfer and its application to the nervous system].
    Ozawa K
    Rinsho Shinkeigaku; 2003 Nov; 43(11):835-8. PubMed ID: 15152479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus-mediated gene transfer to the central nervous system for Parkinson's disease.
    Horellou P; Sabaté O; Buc-Caron MH; Mallet J
    Exp Neurol; 1997 Mar; 144(1):131-8. PubMed ID: 9126162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of ex vivo gene therapy in the treatment of Parkinson's disease.
    Raymon HK; Thode S; Gage FH
    Exp Neurol; 1997 Mar; 144(1):82-91. PubMed ID: 9126156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GDNF therapy for Parkinson's disease.
    Hong M; Mukhida K; Mendez I
    Expert Rev Neurother; 2008 Jul; 8(7):1125-39. PubMed ID: 18590482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.
    Mandel RJ; Snyder RO; Leff SE
    Exp Neurol; 1999 Nov; 160(1):205-14. PubMed ID: 10630205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?
    Lindvall O; Wahlberg LU
    Exp Neurol; 2008 Jan; 209(1):82-8. PubMed ID: 17963752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging restorative treatments for Parkinson's disease.
    Deierborg T; Soulet D; Roybon L; Hall V; Brundin P
    Prog Neurobiol; 2008 Aug; 85(4):407-32. PubMed ID: 18586376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
    Choi-Lundberg DL; Lin Q; Schallert T; Crippens D; Davidson BL; Chang YN; Chiang YL; Qian J; Bardwaj L; Bohn MC
    Exp Neurol; 1998 Dec; 154(2):261-75. PubMed ID: 9878166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.